Itepekimab (Anti-IL-33)
Moderate-to-Severe Asthma
Sponsor Sanofi
2,200 Enrollment Target
190 Trial Sites
5 Countries
June 2027 Est. Completion
About This Trial
Monoclonal antibody targeting IL-33, a key upstream cytokine in allergic inflammation.
Primary Endpoints
- Severe exacerbation rate
- Pre-bronchodilator FEV1
Latest Update
January 2026
Phase 2b showed benefit across all asthma phenotypes including those not responsive to existing biologics.